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Abstract: Background People with HIV (HIV+) may have increased cardiovascular event rates compared
with HIV-negative (HIV-) persons. Cross-sectional data from the United States and Switzerland, based on
coronary artery calcium scan (CAC) and coronary computed tomography angiography (CCTA), suggest,
respectively, increased and similar prevalence of subclinical atherosclerosis in HIV+ vs HIV- persons.
Methods We repeated CAC/CCTA in 340 HIV+ and 90 HIV- study participants >2 years after baseline
CAC/CCTA. We assessed the association of HIV infection, Framingham risk score (FRS), and HIV-
related factors with the progression of subclinical atherosclerosis. Results HIV+ were younger than
HIV- participants (median age, 52 vs 56 years; P < .01) but had similar median 10-year FRS (8.9% vs
9.0%; P = .82); 94% had suppressed HIV viral load. In univariable and multivariable analyses, FRS
was associated with the incidence rate ratio (IRR) of new subclinical atherosclerosis at the follow-up
CAC/CCTA, but HIV infection was not: any plaque (adjusted IRR for HIV+ vs HIV- participants,
1.21; 95% CI, 0.62-2.35), calcified plaque (adjusted IRR for HIV+ vs HIV- participants, 1.06; 95% CI,
0.56-2), noncalcified/mixed plaque (adjusted IRR for HIV+ vs HIV- participants, 1.24; 95% CI, 0.69-
2.21), and high-risk plaque (adjusted IRR for HIV+ vs HIV- participants, 1.46; 95% CI, 0.66-3.20).
Progression of CAC score between baseline and follow-up CAC/CCTA was similar in HIV+ (median
annualized change [interquartile range IQR], 0.41 [0-10.19]) and HIV- participants (median annualized
change [IQR], 2.38 [0-16.29]; P = .11), as was progression of coronary segment severity score (HIV+:
median annualized change [IQR], 0 [0-0.47]; HIV-: median annualized change [IQR], 0 [0-0.52]; P =
.10) and coronary segment involvement score (HIV+: median annualized change [IQR], 0 [0-0.45]; HIV-:
median annualized change [IQR], 0 [0-0.41]; P = .25). Conclusions In this longitudinal CAC/CCTA study
from Switzerland, Framingham risk score was associated with progression of subclinical atherosclerosis,
but HIV infection was not.
DOI: https://doi.org/10.1093/ofid/ofaa438
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Background.  People with HIV (HIV+) may have increased cardiovascular event rates compared with HIV-negative (HIV-) 
persons. Cross-sectional data from the United States and Switzerland, based on coronary artery calcium scan (CAC) and coronary 
computed tomography angiography (CCTA), suggest, respectively, increased and similar prevalence of subclinical atherosclerosis in 
HIV+ vs HIV- persons.
Methods.  We repeated CAC/CCTA in 340 HIV+ and 90 HIV- study participants >2 years after baseline CAC/CCTA. We as-
sessed the association of HIV infection, Framingham risk score (FRS), and HIV-related factors with the progression of subclinical 
atherosclerosis.
Results.  HIV+ were younger than HIV- participants (median age, 52 vs 56 years; P < .01) but had similar median 10-year FRS 
(8.9% vs 9.0%; P = .82); 94% had suppressed HIV viral load. In univariable and multivariable analyses, FRS was associated with the 
incidence rate ratio (IRR) of new subclinical atherosclerosis at the follow-up CAC/CCTA, but HIV infection was not: any plaque 
(adjusted IRR for HIV+ vs HIV- participants, 1.21; 95% CI, 0.62–2.35), calcified plaque (adjusted IRR for HIV+ vs HIV- participants, 
1.06; 95% CI, 0.56–2), noncalcified/mixed plaque (adjusted IRR for HIV+ vs HIV- participants, 1.24; 95% CI, 0.69–2.21), and high-
risk plaque (adjusted IRR for HIV+ vs HIV- participants, 1.46; 95% CI, 0.66–3.20). Progression of CAC score between baseline and 
follow-up CAC/CCTA was similar in HIV+ (median annualized change [interquartile range {IQR}], 0.41 [0–10.19]) and HIV- par-
ticipants (median annualized change [IQR], 2.38 [0–16.29]; P = .11), as was progression of coronary segment severity score (HIV+: 
median annualized change [IQR], 0 [0–0.47]; HIV-: median annualized change [IQR], 0 [0–0.52]; P = .10) and coronary segment in-
volvement score (HIV+: median annualized change [IQR], 0 [0–0.45]; HIV-: median annualized change [IQR], 0 [0–0.41]; P = .25).
Conclusions.  In this longitudinal CAC/CCTA study from Switzerland, Framingham risk score was associated with progres-
sion of subclinical atherosclerosis, but HIV infection was not.
Keyword.:  cardiovascular disease; coronary CT angiography; HIV; longitudinal study; subclinical atherosclerosis.
A major concern in HIV-positive (HIV+) persons includes ac-
celerated atherosclerosis, as underlined by increased rates of 
coronary artery disease (CAD), compared with HIV-negative 
(HIV-) persons. The authors of a recent meta-analysis of the 
global CAD burden estimated the CAD risk to be 2.16-fold 
elevated in HIV+ compared with HIV- persons [1], and US 
guidelines consider that this risk increase persists even with 
successful antiretroviral therapy (ART) [2]. Accelerated ather-
osclerosis in HIV may be mediated by pro-inflammatory and 
pro-coagulant effects in the context of immune activation, del-
eterious viral effects, dyslipidemia, insulin resistance, and in-
creased platelet reactivity due to certain ART agents, high rates 
of smoking and other substance use, and genetic factors [3–6].
Considerable interest has therefore been generated by the 
notion of early diagnosis of subclinical atherosclerosis in 
HIV+ persons using coronary computed tomography angi-
ography (CCTA), which can accurately and reproducibly de-
tect noncalcified plaque when compared with intravascular 
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cardiovascular events than coronary artery calcium (CAC) 
score or carotid intima-media thickness [8]. Three recent, large, 
cross-sectional CCTA studies, conducted in the United States 
[9, 10] and by us in Switzerland [11], however, have not uni-
formly shown more subclinical atherosclerosis in HIV+ com-
pared with HIV- persons, highlighting the need for additional, 
especially longitudinal, studies. Our aims were therefore to in-
vestigate whether subclinical atherosclerosis progresses more 
rapidly over a follow-up period of ≥2  years in HIV+ com-
pared with HIV- persons in Switzerland using CAC/CCTA 
and to evaluate associations of atherosclerosis progression with 
Framingham risk score and HIV infection.
METHODS
Patient Consent Statement
All participants provided written informed consent. The 
study was approved by the local ethics committees (Kantonale 
Ethikkommission Zürich, KEK-ZH Nr. 2013-0103; Commission 
Cantonale d’Éthique de la Recherché sur l’Être Humain, No. de 
Référence CER 13–194).
Study Design and Study Participants
We investigated the association of HIV infection with subclin-
ical CAD by noncontrast computed tomography (CT) scan for 
calculating the CAC score and by CCTA. We obtained base-
line CAC/CCTA scans from 10/2013 to 7/2016 and published 
the main results in 2018 [11] and a detailed analysis of ART 
agents associated with subclinical atherosclerosis in 2019 [12]. 
Enrollment criteria for baseline CAC/CCTA included no docu-
mented CAD/stroke, GFR ≥50 mL/min, no allergy to iodinated 
contrast agent, and no history of atrial fibrillation or other ir-
regular cardiac rhythm. HIV+ persons were aged ≥45 years and 
were asymptomatic participants of the Metabolism and Aging 
Core Project of the Swiss HIV Cohort Study (www.shcs.ch), and 
HIV- participants were referred for clinically indicated CAC/
CCTA. As previously reported [11], we periodically adjusted se-
lection criteria for the HIV- participants for the baseline CCTA/
CAC, resulting in HIV+ and HIV- participants having similar 
median FRS at baseline (8.9% vs 9.0%; P = .82).
Follow-up CAC/CCTA scans were performed from 10/2015 
to 04/2019. The minimum interval between CAC/CCTA scans 
was 2 years based on previous studies that employed interscan 
intervals of 1–2.2 years [13, 14, 15, 16], which allowed the de-
tection of annual CAC score increases of 24%–38% in HIV- 
populations using older-generation CT scanners [15, 17, 18, 
19]. A 2-year minimal CCTA interval has been successfully ap-
plied by others [20, 21].
HIV+ and HIV- participants were similar at baseline with re-
gards to age, gender, and Framingham risk score (FRS) [22]. 
HIV+ participants were invited at routine HIV clinic visits and 
HIV- participants were invited by the study nurse via phone call 
to undergo follow-up CAC/CCTA. Ineligibility for follow-up 
CAC/CCTA in HIV+ and HIV- participants included coro-
nary stenosis >50% at baseline scan, cardiovascular event in the 
interval, eGFR <50  mL/min, unwillingness to undergo repeat 
CAC/CCTA, death, or loss to follow-up.
Data Collection
For HIV+ participants, data were collected within the SHCS, a 
prospective cohort study that has continuously enrolled HIV+ 
adults since 1988 [23]. Demographic, clinical, and laboratory 
data are collected every 6 months using a standardized protocol, 
including detailed information on cardiovascular events, hyper-
tension, diabetes mellitus, smoking, alcohol and drug use, and 
antiretroviral and nonantiretroviral medication. For HIV- par-
ticipants, additional clinical information was obtained by chart 
review at the baseline CAC/CCTA using a structured question-
naire that included the indication for CAC/CCTA referral at 
baseline, verification of inclusion criteria, comorbidities, medi-
cation, smoking, alcohol, and drug use. Vital signs, fasting total, 
low-density lipoprotein cholesterol, high-density lipoprotein 
(HDL) cholesterol, triglycerides, glucose, and creatinine were 
measured at the time of each CAC/CCTA in all participants.
Cardiac Imaging
Cardiac imaging was performed at University Hospitals Zurich 
and Geneva, as previously reported [11, 12]. Because of per-
sonal and institutional restructuring events, we were able to 
recruit HIV- participants only at the Zurich site to undergo fol-
low-up CAC/CCTA.
Statistical Analysis
Co-variables were defined as previously reported [11, 12]. In 
addition, we calculated the area under the individual HIV 
viral load curves and determined the maximum HIV viral 
load between the 2 CAC/CCTA scans for each HIV+ partic-
ipant. Characteristics of HIV+ and HIV- participants were 
compared using the chi-square/Fisher exact test for categorical 
variables and Wilcoxon rank-sum test for continuous vari-
ables. Follow-up time was measured between the 2 CAC/CCTA 
scans. To evaluate the association between HIV infection and 
subclinical atherosclerosis, we analyzed the incidence per 100 
patient-years of subclinical CAD in participants without sub-
clinical CAD at baseline CAC/CCTA using the same 5 separate 
categorical outcomes as in the baseline analyses [11, 12]; that 
is, (1) CAC score >0, (2) any CCTA-detected plaque, (3) cal-
cified plaque, (4) noncalcified/mixed plaque, and (5) high-risk 
plaque, which was defined as plaque with positive remodeling 
(remodeling index ≥1.1) and/or low-attenuation plaque (≤30 
Hounsfield units) [24]. Incidence rate ratios (IRRs) were cal-
culated with univariable Poisson regression and FRS-adjusted 
Poisson regression. The main study end point was the FRS-
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the HIV+ and HIV- participants. FRS adjustment was chosen 
over multivariable models including individual cardiovascular 
risk factors to reduce the number of variables in the model 
and because several individual risk factors were correlated, 
interfering with correct interpretation. Further, using FRS for 
cardiocascular risk stratification facilitates comparison of our 
results with studies from the United States and elsewhere. We 
also performed power considerations by evaluating whether 
a virtual increase (ie, duplication) of the limited numbers of 
HIV- participants would substantially narrow the confidence 
intervals of the FRS-adjusted estimates. Segment involvement 
score (SIS) was calculated using 1 point for each coronary seg-
ment with any plaque; segment severity score (SSS) was calcu-
lated using the total of all segments scored according to lesion 
severity [11]. The annualized changes of CAC scores, SIS, and 
SSS for HIV+ and HIV- participants were compared using 
Wilcoxon rank-sum tests. Statistical analyses were done using 
Stata/SE 16.0 (StataCorp, College Station, TX, USA).
RESULTS
Study Population
Of the 704 study participants (428 HIV+, 276 HIV-) who un-
derwent baseline CAC/CCTA [11], 430 participants had fol-
low-up CAC/CCTA done: These included 340 HIV+ (278/355 
[78%] Zurich participants and 62/73 [85%] Geneva partici-
pants) and 90 HIV- (90/187 [48%] Zurich participants and 0/89 
Geneva participants) with baseline CAC/CCTA. Participant 
disposition is shown in Table  1. There was no evidence for a 
clinically relevant difference in mean (IQR) baseline FRS for 
HIV- participants who did or did not undergo follow-up CAC/
CCTA, that is, 10.2 (5.5–13.4) vs 11.3 (6.7–15.2; P = .11), or for 
HIV+ participants who did or did not undergo follow-up CAC/
CCTA, that is, mean (IQR) baseline FRS, 10.5 (5.9–13.8) vs 11.3 
(6.7–15.1; P = .13). Compared with participants who did not 
have follow-up CAC/CCTA done (n = 274), the study popula-
tion included in the present report (ie, participants who had fol-
low-up CAC/CCTA done; n = 430) was slightly younger, more 
likely to smoke, had less diabetes, had less dyslipidemia, and 
had less high-risk plaque at baseline (Supplementary Table 1).
The median interval between baseline and follow-up scans 
(IQR) was 2.2 (2.1–2.4) years and 3.4 (2.7–3.6) years in HIV+ 
and HIV- participants, respectively. Therefore, all analyses are 
based on annualized rates of change between baseline and 
second CCTA/CAC. Median effective radiation exposure due 
to follow-up CAC/CCTA (IQR) was 1.3 (1.1–1.5) mSv. Baseline 
characteristics of the participants are shown in Table 2. HIV+ 
participants were more likely to be men, were younger, and had 
lower body mass index. HIV+ participants had a lower prev-
alence of hypertension and lower HDL cholesterol levels, and 
they were more likely to smoke and use drugs. However, me-
dian FRS was similar among HIV+ and HIV- participants, as 
were percentages of participants in the low-, intermediate-, and 
high-risk FRS categories. Among the HIV+ participants, men 
who had sex with men were the predominant group, 20% had 
prior AIDS-defining events, and 94% were on ART, of whom 
94% had an undetectable viral load.
Table 1. StudyFlowchart
428 HIV+ participants had
baseline CAC/CCTA
- 355 scans done at University Hospital Zurich
- 73 scans done at University Hospital Geneva
88 HIV+ participants did not
have follow-up CAC/CCTA
- 23 had >50% coronary stenosis
at baseline CCTA
- 9 had eGFR <50ml/min
-5 were lost to follow-up
-3 died
- 1 had a CV event after baseline
CAC/CCTA
- 1 had coronary bypass surgery
after baseline
- 4 had protocol violation
- 42 declined to participate in
follow-up study phase
186 HIV+ participants did not
have follow-up CAC/CCTA
- 38 had >50% coronary stenosis
at baseline CCTA
- 2 had protocol violation
- 78 had baseline scan done at
University Hospital Geneva and
were not invited to do follow-up
scan
- 68 declined to participate in
follow-up study phase
340 HIV+ participants had
follow-up CAC/CCTA
- 278 scans done at University Hospital Zurich
- 62 scans done at University Hospital Geneva
90 HIV– participants had
follow-up CAC/CCTA
- 90 scans done at University Hospital Zurich
- no scans done at University Hospital Geneva
276 HIV– participants had
baseline CAC/CCTA
- 187 scans were at University Hospital Zurich
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Table 2. Characteristics of HIV-Positive and HIV-Negative Study Participants
Characteristic
All Participants  
(n = 430)
HIV+ Participants  
(n = 340)
HIV- Participants 
(n = 90) P Value
Male sex, No. (%) 361 (84.0) 290 (85.3) 71 (78.9) .10a
Age, y 53 (49–58) 52 (49–57) 56 (50–62) <.01b
Ethnicity    <.01a
 White 395 (91.9) 309 (90.9) 86 (95.6)
 Black 26 (6) 22 (6.5) 4 (4.4)
 Other 9 (2.1) 9 (2.6) 0
Body mass index, kg/m2 25.1 (23.0–28.0) 24.9 (22.8–27.8) 26.1 (23.8–28.6) .01b
 <18.5 9 (2.1) 8 (2.4) 1 (1.1) .33a
 ≥18.5–<25 203 (47.2) 167 (49.1) 36 (40.0)
 ≥25–<30 169 (39.3) 130 (38.2) 39 (43.3)
 ≥30 49 (11.4) 35 (10.3) 14 (15.6)
Hypertension 171 (39.8) 113 (33.2) 58 (64.4) <.01a
Diabetes mellitus 15 (3.5) 12 (3.5) 3 (3.3) .61a
Dyslipidemia 166 (38.6) 129 (37.9) 37 (41.1) .33a
Total cholesterol, mmol/L 5.2 (4.6–5.9) 5.2 (4.6–5.8) 5.3 (4.6–6.0) .32b
HDL cholesterol, mmol/L 1.3 (1.1–1.7) 1.3 (1.1–1.6) 1.4 (1.2–1.8) <.01b
LDL cholesterol, mmol/L 3.1 (2.5–3.7) 3.1 (2.5–3.6) 3.2 (2.5–3.8) .56b
Triglycerides, mmol/L 1.4 (1.0–2.1) 1.4 (1.0–2.1) 1.4 (0.9–1.9) .27b
Lipid-lowering drug use     
 At baseline CCTA/CAC 34/430 (7.9)c 18/340 (5.3) 16/90 (17.8) <.01a
 Started thereafter 70/396 (17.7)d 52/322 (16.2) 18/74 (24.3) .13a
Current smoking 134 (31.2) 123 (36.2) 11 (12.2) <.01a
Alcohol consumption    .13a
 None/mild 330 (78.6) 269 (80) 61 (72.6)
 Moderate 85 (20.2) 62 (18.5) 23 (27.4)
 Severe 5 (1.2) 5 (1.5) 0 
Active illicit drug use 11 (2.6) 11 (3.2) 0 .08a
Framingham risk score (10-y risk) 8.9 (5.7–13.8) 8.9 (5.9–13.8) 9.0 (5.5–13.4) .82b
 <10% 241 (56.1) 190 (55.9) 51 (56.7) 1.00a
 10%–20% 154 (35.8) 122 (35.9) 32 (35.6)
 >20% 35 (8.1) 28 (8.2) 7 (7.8)
HIV-specific characteristics     
HIV acquisition mode     
 MSM  204 (60)   
 IDU  34 (10)   
 heterosexual  94 (27.7)   
 Other/unknown  8 (2.4)   
Years HIV-infected  15.1 (6.6–21.8)   
Prior AIDS  69 (20.3)   
CD4 current, cells/µL  600 (447–752)   
CD4 nadir, cells/µL  190 (90–282)   
CD4 nadir <50 cells/µL  55 (16.2)   
HIV viral load max >100 000 copies/mL  218 (64.1)   
HIV viral load-years >50 copies/mL between baseline and follow-up CAC/CCTA  18 (5.7)   
Maximum log10 viral load between baseline and follow-up CAC/CCTA among those 
with viral load >50 copies/mL
 1.67 (1.48–2.08)   
On antiretroviral therapy  318 (93.5)   
On ART, undetectable HIV viral load  300 (94.3)   
ART naïve  4 (1.2)   
ART interrupted  18 (5.3)   
Total years on ART  11.6 (5.3–17.7)   
Hepatitis C seropositivity  48 (14.1)   
All values shown were obtained at the time of baseline cardiac imaging, unless stated otherwise. Data are presented as No. (%) or median (IQR).
Abbreviations: ART, antiretroviral therapy; CAC/CCTA, coronary artery calcium scan/coronary computed tomography angiography; HDL, high-density lipoprotein; IDU, injection drug use; LDL, 
low-density lipoprotein; MSM, men who have sex with men.
aFisher exact test. 
bWilcoxon rank-sum test. 
cStatin in all participants except 1 HIV+ participant on a fibrate. 
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Progression of Subclinical CAD in Patients With Subclinical CAD at 
Baseline CAC/CCTA
At follow-up scan, CAC increased as a function of baseline CAC 
(Figure 1A) and baseline FRS category (Figure 1B). Similarly, at 
follow-up scan, coronary SSS and SIS increased as a function of 
baseline SSS, baseline SIS, and baseline FRS category (Figure 1C 
and D; Supplementary Figure 1C and D). Visual inspection of 
Figure 1B–D suggests no effect of HIV infection on CAC, SSS, 
or SIS progression.
Progression of Subclinical CAD, Median Annualized Change
HIV infection was not associated with progression of CAC 
score, SSS, or SIS between baseline and follow-up CAC/CCTA. 
The median annualized change (IQR) in CAC score was 0.41 
(0–10.19) in HIV+ and 2.38 (0–16.29) in HIV- study partici-
pants (P = .11). The median annualized changes (IQR) in SSS 
and SIS were 0 (0–0.47) and 0 (0–0.52; P = .10), and 0 (0–0.45) 
and 0 (0–0.41), respectively (P = .25).
Annualized Incidence Rate of Subclinical Atherosclerosis at Follow-up 
CAC/CCTA, Univariable Analysis
The incidence rates of new subclinical CAD per 100 person-
years of follow-up in HIV+ and HIV- participants without any 
subclinical CAD at baseline CAC/CCTA are shown in Figure 2 
(upper panel) and Supplementary Table 2. HIV infection was 
not associated with any plaque (compared with HIV- partici-
pants; annualized IRR, 0.97; 95% CI, 0.46–2.05), calcified plaque 
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Figure 1.  Association of baseline CAC score, FRS, SSS, and SIS with measurements at follow-up CAC/CCTA in HIV+ and HIV- study participants. A, Relationship be-
tween CAC at baseline and follow-up scans. B, Regression analysis of annualized CAC increase from baseline to follow-up CAC determination. Marginal effects from robust 
regression analysis with interaction terms of CAC at visit 1, 1-year Framingham risk at visit 1, and HIV status. C, Probability of SSS increase from baseline to follow-up CCTA. 
Marginal effects from logistic regression analysis with interaction terms of SSS at baseline CCTA, 1-year Framingham risk at baseline CCTA, and HIV status. For visual clarity, 
no 95% CIs are shown. For figures with 95% CI, see Supplementary Figure 1C. D, Probability of SIS increase from baseline to follow-up CCTA. Marginal effects from logistic 
regression analysis with interaction terms of SIS at visit 1, 1-year Framingham risk at visit 1, and HIV status. For visual clarity, no 95% confidence intervals are shown. For 
figures with 95% CIs, see Supplementary Figure 1D. Abbreviations: CAC, coronary artery calcium scan; CCTA, coronary computed tomography angiography; FRS, Framingham 
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plaque (annualized IRR, 1.22; 95% CI, 0.68–2.17), high-risk 
plaque (annualized IRR, 1.41; 95% CI, 0.64–3.10), any coronary 
stenosis (annualized IRR, 1.14; 95% CI, 0.59–2.22), stenosis of 
≥50% (annualized IRR, 1.16; 95% CI, 0.52–2.59), and stenosis 
of ≥70% (annualized IRR, 0.97; 95% CI, 0.30–3.10).
Annualized Incidence Rate of New Subclinical Atherosclerosis at 
Follow-up CAC/CCTA, Multivariable Analysis Adjusted for FRS
FRS (per point increase) was associated with any plaque (IRR, 
1.48; 95% CI, 1.03–2.13), calcified plaque (IRR, 1.70; 95% CI, 
1.30–2.23), noncalcified/mixed plaque (IRR, 1.66; 1.27–2.17), 
high-risk plaque (IRR, 1.78; 95% CI, 1.24–2.54), any coronary 
stenosis (IRR, 1.66; 95% CI, 1.27–2.17), stenosis of ≥50% (IRR, 
2.14; 95% CI, 1.51–3.03), and stenosis of ≥70% (IRR, 2.44; 







































































































Figure 3.  Adjusted incidence rate ratio of new subclinical CAD in HIV+ and 













































































































































































































Figure 2.  Incidence rates of new subclinical CAD (upper panel) and mean annual increase of coronary CAC, SSS, and SIS scores (lower panel) in HIV+ and HIV- study 
participants, univariable analysis. The incidence rates (upper panel) shown here are tabulated in Supplementary Table 1. Abbreviations: CAC, coronary artery calcium scan; 
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not associated with any plaque (annualized IRR, 1.21; 95% CI, 
0.62–2.35), calcified plaque (annualized IRR, 1.06; 0.56–2), 
noncalcified/mixed plaque (annualized IRR, 1.24; 95% CI, 
0.69–2.21), high-risk plaque (annualized IRR, 1.46; 0.66–3.20), 
stenosis of ≥50% (annualized IRR, 1.17; 95% CI, 0.53–2.62), 
or stenosis of ≥70% (annualized IRR, 0.95; 95% CI, 0.30–3.03) 
(Figure 3).
Associations Between HIV Viral Load and Progression of Subclinical CAD
Because HIV was not associated with subclinical atherosclerosis 
progression, we did not conduct any subanalyses of HIV-related 
variables. However, because accelerated plaque progression was 
seen in HIV+ participants with incomplete HIV suppression in 
the MACS study [25], we analyzed maximal HIV viral load and 
area under the HIV viral load curve since baseline CAC/CCTA. 
These variables were not associated with subclinical atheroscle-
rosis progression in our data set (Supplementary Table 3).
Power Considerations
Because of limited numbers of HIV- participants, we conducted 
a virtual exercise of duplicating the number of HIV- partici-
pants. The conclusion that HIV infection is not associated with 
progression of any of the subclinical atherosclerosis end points 
remained unchanged, that is, 95% confidence intervals always 
included the value 1 even after a virtual, up to 100
 
000-fold 
increase in the number of HIV- participants (data not shown).
DISCUSSION
To our knowledge, this is the first longitudinal study to com-
pare subclinical coronary atherosclerosis progression be-
tween HIV+ and HIV- persons from Europe. Using CAC 
and CCTA, and after adjusting for multiple traditional and 
HIV-related CAD risk factors, we found no evidence of ac-
celerated progression of subclinical CAD in Swiss HIV+ per-
sons, including calcified, noncalcified, and high-risk plaque. 
As expected, age and FRS were significantly associated with 
atherosclerosis progression. HIV infection, however, was not. 
Our findings are reassuring for HIV+ persons, their families, 
and their treating physicians, as they provide additional ev-
idence that attenuates concerns about accelerated athero-
sclerosis or even accelerated aging in HIV+ individuals on 
effective ART. These results extend our recent cross-sectional 
CAC/CCTA results [11] that prompted editorialists to spec-
ulate whether the prevalent notion of increased CAD risk 
in HIV [1, 2] amounted to “much ado about nothing” [26]. 
This conclusion may apply particularly to HIV+ persons in 
Switzerland, considering the regular patient follow-up in the 
setting of the well-established SHCS, high rates of viral con-
trol with modern ART regimens, decreasing smoking rates 
in recent years [27], and no evidence of increased cardiovas-
cular event incidence compared with the community-based, 
HIV-negative CoLaus control cohort [28].
Our cross-sectional CAC/CCTA results were consistent 
with a large CCTA study in African American patients from 
Baltimore, Maryland [10], whereas the US Multicenter AIDS 
Cohort Study (MACS) suggested a higher prevalence of 
noncalcified plaque in HIV+ vs HIV- men who have sex with 
men [9]. In their longitudinal CAC/CCTA follow-up report, 
the MACS recently noticed no overall difference in subclin-
ical atherosclerosis progression in HIV+ vs HIV- persons [25], 
consistent with our longitudinal CAC/CCTA findings from 
Switzerland presented here. Evidence of accelerated plaque pro-
gression in MACS was restricted to the HIV+ participants with 
incomplete HIV suppression [25]. Insufficient viral control is 
associated with immune activation and consequent delete-
rious pro-inflammatory and pro-coagulatory, atherosclerosis-
promoting mechanisms [6, 29, 30]. In our Swiss HIV+ persons, 
incomplete HIV suppression was uncommon: only 6% of our 
HIV+ participants had a detectable HIV viral load during fol-
low-up, compared with 30% in MACS [25]. Therefore, suc-
cessful HIV treatment in our study may have prevented us from 
detecting any atherosclerosis-promoting effects of suboptimal 
HIV control.
Our study has strengths and limitations. The strengths in-
clude this being the first large-scale, longitudinal study com-
paring subclinical atherosclerosis by CAC/CCTA in HIV+ and 
HIV- persons in Europe. Our HIV+ participants were followed 
in the well-established SHCS [23], which allowed us to exploit 
all relevant clinical, laboratory, and HIV-related data. Our study 
was limited by the number of HIV- participants available for 
follow-up CAC/CCTA. However, FRS were similar in the HIV+ 
and HIV- participants at baseline, and we calculated that even 
enrolling 100
 
000 times more HIV- participants with similar 
FRS as the HIV+ participants would not result in statistically 
significant associations between HIV infection and atheroscle-
rosis progression. Because we and the investigators of the 2 US 
CCTA studies in PLWH [9, 10] did not formally match HIV+ 
and HIV- participants on cardiovascular risk factors, there were 
differences in the prevalence of cardiovascular risk factors in 
HIV+ and HIV- participants in all 3 studies [9–11]. However, 
the 10-year median FRS of our Swiss HIV+ and HIV- partici-
pants were comparable. In 2 other studies, HIV- participants 
were extensively matched on CAD risk factors to the HIV+ 
participants, and no difference in CIMT progression [31] and a 
similar prevalence of noncalcified coronary plaque were docu-
mented [32]. Few of our participants were >65 years old, and 
only 16% were women; therefore, our results should be inter-
preted with caution in these populations.
Although we compared asymptomatic HIV+ with sympto-
matic HIV- referral patients, we recorded a similar prevalence 
of >50% coronary stenosis at the baseline scan [11], strongly 
suggesting that the symptoms that prompted CCTA referral 
of the HIV- persons were mostly of noncoronary origin [33]. 
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where family doctors have a low threshold for referring pa-
tients with typical chest pain and those with comorbitities and 
at least moderate cardiovascular risk for invasive coronary an-
giography; that is, Swiss doctors seem to refer mainly patients 
with atypical chest pain and low cardiovascular risk for CCTA 
or other noninvasive testing [34, 35]. Finally, when we de-
signed the study, the funding agency (Swiss National Science 
Foundation) agreed with us that recruitment of asymptomatic 
HIV- participants would be problematic, for 3 reasons: (i) com-
plexity of recruiting asymptomatic HIV- participants with a 
risk factor profile sufficiently similar to HIV+ participants; (ii) 
among asymptomatic HIV- participants volunteering to un-
dergo 2 CCTA/CACs 2  years apart, the following individuals 
are likely to be overrepresented: those who have, for example, 
symptoms that they feel are unexplained or inadequately ad-
dressed by their providers, persons who perceive themselves to 
have a family history of cardiovascular disease, those who are 
extremely health conscious, the “worried well” etc.; (iii) limited 
motivation of asymptomatic participants to attend the 2-year 
follow-up CCTA/CAC (risk of an unacceptably high dropout 
rate). Our best assessment was therefore that the most appro-
priate method to recruit HIV- participants was considering the 
consecutive HIV-negative patients referred for CCTA. The va-
lidity of this approach was confirmed by the lack of enrichment 
for CAD in our HIV- participants.
In conclusion, our longitudinal CAC/CCTA study reassur-
ingly finds no significant differences in coronary plaque pro-
gression in HIV+ persons compared with HIV- persons in 
Switzerland. The similar myocardial infarction incidence rates 
in HIV+ and HIV- persons in Switzerland [28] are consistent 
with reports from California [36] and Denmark [37]. In aggre-
gate, these data serve to further attenuate concerns about ac-
celerated atherosclerosis in persons with well-controlled HIV 
infection.
Supplementary Data
Supplementary materials are available at Open Forum Infectious Diseases 
online. Consisting of data provided by the authors to benefit the reader, 
the posted materials are not copyedited and are the sole responsibility 
of the authors, so questions or comments should be addressed to the 
corresponding author.
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